Thyroid Hormones in ADPKD

Plain-language summary

This is an observational study that examines thyroid hormones through blood samples in people with autosomal dominant polycystic kidney disease (ADPKD). Men and women aged 18 and older diagnosed with ADPKD by kidney ultrasound or genetic testing were included. It is a non-interventional (observational) study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

Mario Negri Institute for Pharmacological Research

Intervention

Blood sampling

Start date

2/1/2023

Estimated completion

3/25/2024

Countries

Italy

Related genes

Locations

• Ranica, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Male and female ≥18 years old;
2. Diagnosis of ADPKD based on renal ultrasonography or genetic test;
3. Written informed consent

Exclusion Criteria:

1. Diagnosis of Hashimoto's disease, hyperthyroidism or pituitary disease or any other condition undergoing levothyroxine replacement
2. Patient with hypothyroidism treated with drug therapy
3. Active treatment with Tolvaptan and/or Octreotide-LAR;
4. Regular treatment with amiodarone, lithium, interferon or immunosuppressive drugs including steroids;
5. Active malignancy or acute or chronic inflammatory disease, HIV;
6. Dialysis or kidney transplantation;
7. Diabetes mellitus;
8. Hypocaloric diet or current dietary approaches to obtain weight loss.
9. Legal incapacity or any evidence that the patient will not be able to understand the study aims and procedures.